Discussions with leaders: JNM contributor Ken Herrmann conducts an interview with Stefano Buono, founder of Advanced Accelerator Applications, on the evolution of international radiopharmaceutical distribution and his current activities.
Page 1659
Theranostics in nuclear medicine education: Bodei and colleagues discuss and provide suggestions for the redesign of nuclear medicine training curricula to include theranostics and create new training pathways and fellowships.
Page 1663
Molecular imaging of reporter genes: Serganova and Blasberg detail the history and current status of molecular imaging with reporter genes, including radionuclide-based imaging, and describe potential near-term applications.
Page 1665
Neuroimaging of CRCI, PTSD, and TBI: Alcantara and colleagues offer an educational review of clinical features and therapeutic approaches in evaluation and management of cancer- and chemotherapy-related cognitive impairment, posttraumatic stress disorder, and traumatic brain injury.
Page 1682
Molecular imaging of P-selectin: Perkins and colleagues outline the role of P-selectin in cardiovascular inflammatory conditions and its translation as an early inflammatory biomarker for several molecular imaging modalities for diagnosis and therapeutic planning.
Page 1691
Dynamic PET tumor control probability model: Thorwarth and colleagues evaluate an imaging parameter–response relationship between the extent of tumor hypoxia quantified by dynamic 18F-FMISO PET/CT and risk of relapse after radiotherapy in patients with head and neck cancer.
Page 1698
18F-Choline PET/mpMRI cost-effectiveness: Barnett and colleagues assess the cost-effectiveness of 18F-choline PET/multiparametric MRI versus mpMRI alone for detection of primary prostate cancer with a Gleason score of ≥3 + 4 and elevated prostate-specific antigen levels.
Page 1705
NaF-PET/CT in prostate cancer: Zacho and colleagues determine whether additional 18F-sodium fluoride PET/CT imaging improves prognostic accuracy in initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy.
Page 1713
Evaluation of 68Ga-DOTATATE uptake: Gålne and colleagues explore the question of whether long-acting somatostatin analog treatment changes the uptake of 68Ga-DOTATATE in patients with neuroendocrine tumors.
Page 1717
68Ga-Pentixafor PET/CT in WM: Luo and colleagues report on a prospective cohort study of PET performance with 68Ga-pentixafor, which targets chemokine receptor 4 in Waldenström macroglobulinemia (also called lymphoplasmacytic lymphoma) and compare this with 18F-FDG results.
Page 1724
Quantitative analysis of 18F-DCFPyL PET: Jansen and colleagues perform a full pharmacokinetic analysis of this second-generation 18F-labeled prostate-specific membrane antigen ligand and propose and validate simplified methods for 18F-DCFPyL uptake quantification in patients with prostate cancer.
Page 1730
18F-PSMA-11 PET/CT for prostate cancer: Piron and colleagues evaluate the administration safety and radiation dosimetry of 18F–prostate-specific membrane antigen–11 in patients with suspected prostate cancer recurrence after previous treatment.
Page 1736
Imaging fibroblast activity after MI: Varasteh and colleagues investigate the feasibility of PET imaging of activated fibroblasts with a new 68Ga-labeled fibroblast activation protein inhibitor in a preclinical model of myocardial infarction.
Page 1743
Imaging acute doxorubicin cardiotoxicity: McCluskey and colleagues evaluate an 18F-labeled lipophilic phosphonium cation as a cardiac imaging agent, comparing it with PET and SPECT tracers to assess utility for imaging cardiotoxicity in an acute doxorubicin model.
Page 1750
Dopamine in atypical parkinsonism: Kaasinen and colleagues conduct a metaanalysis of striatal presynaptic dopaminergic function imaging in multiple-system atrophy parkinsonism and cerebellar variants, progressive supranuclear palsy, corticobasal syndrome, and Parkinson disease.
Page 1757
Saving time or dose in neuro-PET: Schiller and colleagues determine the effect of reduced acquisition time for 18F-FDG PET studies of Alzheimer dementia and frontotemporal dementia to derive a limit for reductions of acquisition time and administered activity.
Page 1764
Quantification method for amyloid-β: Tahmi and colleagues describe development and validation of a technique that quantifies the extent of brain amyloid-β pathology on a millimeter-by-millimeter scale using data from PET scans.
Page 1771
11C-UCB-J and AD treatment effects: Toyonaga and colleagues perform longitudinal 11C-UCB-J PET imaging on Alzheimer disease mice to measure the treatment effects of saracatinib, which previously demonstrated synaptic changes with postmortem methods.
Page 1780
Small-animal PET in AppNL-G-F mice: Sacher and colleagues combine behavioral tests with serial PET imaging in AppNL-G-F knock-in mice to validate this imaging approach in amyloidosis and neuroinflammation as a tool for therapy monitoring.
Page 1787
124I-Omburtamab in leptomeningeal tumors: Pandit-Taskar and colleagues study the role of 124I-omburtamab given intraventricularly in PET assessment of distribution and radiation doses before 131I-omburtamab therapy in metastatic leptomeningeal disease and compare it with estimates from cerebrospinal fluid sampling.
Page 1794
A PHITS-based dosimetry tool: Carter and colleagues describe development, validation, and performance of PARaDIM, a Particle and Heavy Ion Transport Code System–based freeware application for implementing tetrahedral mesh-type phantoms in absorbed dose calculations.
Page 1802
Characterization of 18F-hGTS13: Beinat and colleagues detail the development of an improved PET radiotracer for measuring xC− activity with increased tumor uptake and reduced uptake in inflammatory cells compared with 18F-FSPG.
Page 1812
Performance evaluation of LFER 150: Sarnyai and colleagues report on the performance of the LFER 150 PET/CT device, a large–field-of-view extreme-resolution portable research imager for nonhuman primates, using the National Electrical Manufacturers Association NU 4-2008 standard protocol.
Page 1818
89Zr-mAb PET and target engagement: Jauw and colleagues document nonspecific uptake in normal tissues as a first step toward quantification of monoclonal antibody target engagement using 89Zr-immuno-PET, as a predictor of treatment toxicity in normal tissues and efficacy in tumors.
Page 1825
- © 2019 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.